PharmStockPharmacy Stock

Vaniqa
Vaniqa

94.33
Used to address skin conditions, this generic medicine reduces the growth of unwanted hair by blocking specific enzymes required for hair follicle development.
Ingredient
Eflornithine
Category
Skin Care
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Eflornithine
Reference Brand
Eflornithine
Product Origin
Generic Alternative
Reference Manufacturer
Allergan
Product Form
Cream
Regulatory Classification
Prescription Only Medicine
Primary Category
Skin Care
Product Category
Ornithine Decarboxylase Inhibitor
Pharmacological Class
Topical Eflornithine
Clinical Indications
Excessive facial hair
Manufacturer Description
Developed to mitigate facial hair overgrowth to support epidermal texture and alleviate hair density.
Mechanism of Action
Irreversibly inhibits ornithine decarboxylase in hair follicles, stopping the synthesis of polyamines required for hair growth.
Route of Administration
Topical
Onset Time
4–8 weeks
Contraindications
Hypersensitivity to eflornithine
Severe Adverse Events
Severe localized contact dermatitis — requires immediate medical attention
Common Side Effects
Local skin redness, Burning, Stinging
Uncommon Side Effects
Dry skin, Pruritus, Folliculitis
Pregnancy Safety Warnings
TGA Category C: Use if potential benefits outweigh risks. Breastfeeding: Consult a doctor.
Age Restrictions
Approved for children over twelve years and adults.
Storage Guidelines
Store below 25°C. Do not freeze.
Information related to Vaniqa is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
where to order Skin Care AU - Elidel Australia